Novel vanilloid receptor-1 antagonists: 1. Conformationally restricted analogues of trans-cinnamides

Journal of Medicinal Chemistry

Volumn 50, Issue 15, 2007, Pages 3497-3514

  Norman, Mark H ^a   Zhu, Jiawang ^a   Fotsch, Christopher ^a   Bo, Yunxin ^a   Chen, Ning ^a   Chakrabarti, Partha ^a   Doherty, Elizabeth M ^a   Gavva, Narender R ^a   Nishimura, Nobuko ^a   Nixey, Thomas ^a   Ognyanov, Vassil I ^a   Rzasa, Robert M ^a   Stec, Markian ^a   Surapaneni, Sekhar ^a   Tamir, Rami ^a   Viswanadhan, Vellarkad N ^a   Treanor, James J S ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACRYLAMIDE DERIVATIVE; AMG 9810; CAPSAICIN; CINNAMAMIDE DERIVATIVE; FREUND ADJUVANT; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM TRANSPORT; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CONFORMATION; DRUG EFFICACY; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HYPERALGESIA; HYPOTHERMIA; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN; PAIN; PROTEIN EXPRESSION; THERMAL ANALYSIS;

ADMINISTRATION, ORAL; AMINOQUINOLINES; ANALGESICS; ANIMALS; BIOLOGICAL AVAILABILITY; BODY TEMPERATURE; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; HYPERALGESIA; INJECTIONS, INTRAVENOUS; MALE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PYRIMIDINES; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS; TRPV CATION CHANNELS;

EID: 34547573343     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070189q     Document Type: Article

References (88)

1. The History of Anesthesia, Proceedings of the 5th International Symposium on the History of Anesthesia, Santiago, Spain, September 19-23, 2001, 1st ed.; Diz, J. C., Franco, A., Bacon, D. R., Rupreht, J., Alvarez, J., Eds.; Elsevier: Amsterdam, 2003.
2. McCurdy, C. R.; Scully, S. S. Analgesic Substances Derived from Natural Products (Natureceuticals). Life Sci. 2005, 78 (5), 476-484.
3. Verosick, F. T., Jr. Why We Hurt: The Natural History of Pain; Hardcort, Inc.: Orlando, FL, 2000; p 141.
4. Rome, J. Mayo Clinic on Chronic Pain, 2nd ed.; Mayo Clinic Health Information: New York, NY, 2002 (distributed by Kensington Publishing Corporation).
5. Lembeck, F. Columbus, Capsicum and Capsaicin: Past, Present and Future. Acta Physiol. Hung. 1987, 69, 265-273.
6. Suzuki, T.; Iwai, K. Constituents of Red Pepper Species: Chemistry, Biochemistry, Pharmacology, and Food Science of the Pungent Principle of Capsicum Species. In The Alkaloids: Chemistry and Pharmacology; Brossi, A., Ed.; Academic Press: Orlando, FL, 1984; Vol. 23, Chapter 4.
7. (a) Szallasi, A.; Blumberg, P. M. Vanilloid (Capsaicin) Receptors and Mechanisms Pharmacol. Rev. 1999, 51 (2), 159-211.
8. (b) Naj, A. Peppers. A Story of Hot Pursuits; Alfred A. Knopf: New York, 1992.
9. Brand names of some topical analgesic creams containing capsaicin: Capsin, Capzasin-HP Arthritis Formula, Capzasin-P, Dolorac, Dr. s Cream, Menthac Arthritis Cream with Capsaicin, NO PAIN, RT Capsin, Salonpas Pain Patch with Capsaicin, Trixaicin, Trixaicin HP, Zostrix, Zostrix Sports, Zostrix-HP.
10. Vanilloid, receptor-1 is referred to as TRPV1 in this report according to the adopted nomenclature: Montell, C.; Birnbaumer, L.; Flockerzi, V.; Bindels, R. J.; Bruford, E. A.; Caterina, M. J.; Clapham, D. E.; Harteneck, C.; Heler, S.; Julius, D.; Kojima, I.; Mori, Y.; Penner, R.; Prawitt, D.; Scharenberg, A. M.; Schultz, G.; Shimizu, N.; Zhu, M. X. A Unified Nomenclature for the Superfamily of TRP Cation Channels. Mol. Cell 2002, 9, 229-231.
11. Caterina, M. J.; Schumacher, M. A.; Tominaga, M.; Rosen, T. A.; Levine, J. D.; Julius, D. The Capsaicin Receptor: A Heat-Activated Ion Channel in the Pain Pathway. Nature 1997, 389, 816-824.
12. Appendino, G.; Munoz, E.; Fiebich, B. L. TRPV1 (Vanilloid Receptor, Capsaicin Receptor) Agonists and Antagonists. Expert Opin. Ther. Pat. 2003, 13, 1825-1837.
13. Rami, K. H.; Gunthorpe, M. J. The Therapeutic Potential of TRPV1 (VR1) Antagonists: Clinical Answers Await. Drug Discovery Today 2004, 1, 97-104.
14. Breitenbucher, G.; Chaplan, S. R.; Carruters, N. I. The TRPV1 Vanilloid Receptor: A Target for Therapeutic Intervention. Ann. Rep. Med. Chem. 2005, 40, 185-198 (edited by A. M. Doherty).
15. Walker, K. M.; Urban, L.; Medhurst, S. J.; Patel, S.; Panesar, M.; Fox, A. J.; McIntyre, P. The VR1 Antagonist Capsazepine Reverses Mechanical Hyperalgesia in Models of Inflammatory and Neuropathic Pain. J. Pharmacol. Exp. Ther. 2003, 304, 56-62.
16. Caterina, M. J.; Leffler, A.; Malmberg, A. B.; Martin, W. J.; Trafton, J.; Petersen-Zeitz, K. R.; Koltzenburg, M.; Basbaum, A. I.; Julius, D. Impaired Nociception and Pain Sensation in Mice Lacking the Capsaicin Receptor. Science 2000, 288, 306-313.
17. Davis, J. B.; Gray, J.; Gunthrope, M. J.; Hatcher, J. P.; Davey, P. T.; Overend, P.; Harries, M. H.; Latcham, J.; Clapham, C.; Atkinson, K.; Hughes, S. A.; Ranee, K.; Grau, E.; Harper, A. J.; Pugh, P. L.; Rogers, D. C.; Bingham, S.; Randall, A.; Sheardown, S. A. Vanilloid Receptor-1 is Essential for Inflammatory Thermal Hyperalgesia. Nature 2000, 405, 183-187.
18. Szallasi, A.; Appendino, G. Vanilloid Receptor TRPV1 Antagonists as the Next Generation of Painkillers. Are We Putting the Cart Before the Horse? J. Med. Chem. 2004, 47, 2717-2723.
19. Planellls-Cases, R.; Garcia-Martinez, C.; Royo, M.; Perez-Paya, E.; Carreno, C.; Albericio, F.; Messeguer, A.; Ferrer-Montiel, A. Small Molecules Targeting the Vanilloid Receptor Complex as Drugs for Inflammatory Pain. Drugs Future 2003, 28, 787-795.
20. (a) McDonnell, M. E.; Zhang, S.-P.; Nasser, N.; Dubin, A. E.; Dax, S. L. 7-Hydroxynaphthalen-1-yl-urea and -amide Antagonists of Human Vanilloid Receptor 1. Bioorg. Med. Chem. Lett. 2004, 14, 531-534.
21. (b) Rami, H. R.; Thompson, M.; Wyman, P.; Jerman, J. C.; Egerton, J.; Brough, S.; Stevens, A. J.; Randall, A. D.; Smart, D.; Gunthorpe, M. J.; Davis, J. B. Discovery of Small Molecule Antagonists of TRPV1. Bioorg. Med. Chem. Lett. 2004, 14, 3631-3634.
22. (c) Jetter, M. C.; Youngman, M. A.; McNally, J. J.; Zhang, S.-P.; Dubin, A. E.; Nasser, N.; Dax, S. L. N-Isoquinolin-5-yl-N′-aralkyl- urea and -amide Antagonists of Human Vanilloid Receptor 1. Bioorg. Med. Chem. Lett. 2004, 3053-3056.
23. (d) Gomtsyan, A.; Bayburt, E. K.; Schmidt, R. G.; Zheng, G. Z.; Perner, R. J.; Didomenico, S.; Koenig, J. R.; Turner, S.; Jinkerson, T.; Drizin, I.; Hannick, S. M.; Macri, B. S.; McDonald, H. A.; Honore, P.; Wismer, C. T.; Marsh, K. C. Wetter, J.; Stewart, K, D.; Oie, T.; Jarvis, M. F.; Surowy, C. S.; Faltynek, K. R.; Lee, C.-H. Novel Transient Receptor Potential Vanilloid 1 Receptor Antagonists for the Treatment of Pain: Structure-Activity Relationships for Ureas with Quinoline, Isoquinoline, Quinazoline, Phthalazine, Quinoxaline, and Cinnoline Moieties. J. Med. Chem. 2005, 48, 744-752.
24. (e) Honore, P.; Wismer, C. T.; Mikusa, J.; Zhu, C. Z.; Zhong, C.; Gauvin, D. M.; Gomtsyan, A.; Kouhen, R. E.; Lee, C.-H.; Marsh, K.; Sullivan, J. P.; Faltynek, C. R.; Jarvis M. F. A-425619 [1-Isoquinolin-5-yl-3-(4-trifluoromethyl- benzyl)-urea], a Novel Transient Receptor Potential Type VR1 Receptor Antagonist, Relieves Pathophysiological Pain Associated with Inflammation and Tissue Injury in Rats. J. Pharmacol. Exp. Ther. 2005, 314, 410-421.
25. (f) Rami, H. R.; Thompson, M.; Stemp, G.; Fell, S.; Jerman, J. C.; Stevens, A. J.; Smart, D.; Sargent, B.; Sanderson; D.; Randall, A. D.; Gunthorpe, M. J.; Davis, J. B. Discovery of SB-705498: A Potent, Selective and Orally Bioavailable TRPV1 Antagonist Suitable for Clinical Development. Bioorg. Med. Chem. Lett. 2006, 16, 3287-3291.
26. (a) Lee, J.; Kang, S.-U.; Kil, M.-J.; Shin, M.; Lim, J.-O.; Choi, H.-K.; Jin, M.-K.; Kim, S. Y.; Kim, S.-E.; Lee, Y.-S.; Min, K.-H.; Kim, Y.-K.; Ha, H.-J.; Tran, R.; Welter, J. D.; Wang, Y.; Szabo, T.; Pearce, L. V.; Lundberg, D. J.; Toth, A.; Pavlyukovets, V. A.; Morgan, M. A.; Blumberg, P. M. Analysis of Structure-Activity Relationships for the 'A-Region' of N-(4-t- Butylbenzyl)-N′-[4-(methylsulfonylamino)benzyl]thiourea Analogues as TRPV1 Antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 4136-4142.
27. (b) Suh, Y.-G.; Lee, Y.-S.; Min, K.-H.; Park, O.-H.; Kim, J.-K.; Seung, H.-S.; Seo, S.-Y.; Lee, B.-Y.; Nam, Y.-H.; Lee, K.-O.; Kim, K.-D.; Park, H.-G.; Lee, J.; Oh, U.; Lim, J.-O.; Kang, S.-U.; Kil, M.-J.; Koo, J.; Shin, S. S.; Joo, Y.-H.; Kim, J. K.; Jeong, Y.-S.; Kim, S.-Y.; Park, Y.-H. Novel Potent Antagonists of Transient Receptor Potential Channel, Vanilloid Subfamily Member 1: Structure-Activity Relationship of 1,3-Diarylalkyl Thioureas Possessing New Vanilloid Equivalents. J. Med. Chem. 2005, 48, 5823-5836.
28. (c) Lee, J.; Kim, S. Y.; Lee, J.; Kang, S.-U.; Kil, M.-J.; Choi, H.-K.; Jin, M.-K.; Wang, Y.; Toth, A.; Pearce, L. V.; Lundberg, D. J.; Tran, R.; Blumberg, P. M. Analysis of Structure-Activity Relationships with the N-(3-Acyloxy-2-benzyl-propyl)-N′-[4-(methylsulfonylamino) benzyl]thiourea Template for Vanilloid Receptor 1 Antagonism. Bioorg. Med. Chem. 2004, 12, 3411-3420.
29. (d) Toth, A.; Blumberg, P. M.; Chen, Z.; Kozikowski, A. P. Design of a High-Affinity Competitive Antagonist of the Vanilloid Receptor Selective for the Calcium Entry-Linked Receptor Population. Mol. Pharmacol. 2004, 65, 282-291.
30. (a) Davis, J. B.; Smart, D.; Gunthrope, M. J. The Vanilloid Receptor and Vanilloid Receptor-Like Genes: A Hot Topic Getting Hotter. Cell Transm. 2002, 18, 3-9.
31. (b) Gunthrope, M. J.; Rami, H. K.; Jerman, J. C.; Smart, D.; Gill, C. H.; Soffin, E. M.; Hannan, S. L.; Lappin, S. C.; Egerton, J.; Smith, G. D.; Worby, A.; Howett, L.; Owen, D.; Nasir, S.; Davies, C. H.; Thompson, M.; Wyman, P. A.; Randall, A. D.; Davis, J. B. Identification and Characterization of SB-366791, a Potent and Selective Vanilloid Receptor (VR1/TRPV1) Antagonist. Neuropharmacology 2004, 46, 133-149.
32. (c) Park, H.; Choi, J.; Kim, M.; Choi, S.; Park, M.; Lee, J.; Suh, Y.-G.; Cho, H.; Oh, U.; Kim, H.-D.; Joo, Y. H.; Shin, S. S.; Kim J. K.; Jeong, Y. S.; Koh, H.-J.; Park, Y.-H.; Jew, S. Biarylcarboxybenzamide Derivatives as Potent Vanilloid Receptor (VR1) Antagonistic Ligands. Bioorg. Med. Chem. Lett. 2005, 15, 631-634. Corrigendum. Bioorg. Med. Chem. Lett. 2005, 15, 1955.
33. (a) Doherty, E. M.; Fotsch, C.; Bo, Y.; Chakrabarti, P.; Chen, N.; Gavva, N.; Han, N.; Kelly, M. G.; Kincaid, J.; Klionsky, L.; J.; Liu, Q.; Ognyanov, V. I.; Tamir, R.; Wang, Q.; Zhu Z.; Norman, M. H.; Treanor, J. J. S. Discovery of Potent, Orally Available Vanilloid Receptor-1 Antagonists. Structure-Activity Relationship of N-Aryl Cinnamides. J. Med. Chem. 2005, 48, 71-90.
34. (b) Doherty, E. M.; Zhu, J.; Stec, M.; Norman M. H.; Ognyanov, V. I.; Fotsch, C. H.; Chen, N.; Chakrabarti, P. P.; Pettus, L. H.; Wang H.; Wang X; Arasasingham, P. Vanilloid Receptor Ligands and Their Use in Treatments. WO 2003/049702 A3, 2003.
35. (c) Gavva, N. R.; Bannon, A. W.; Tamir, R.; Wang, Q.; Zhu, D.; Le, A.; Youngblood, B.; Kuang, R.; Deng, H.; Wang, J.; Surapaneni, S.; Magal, E.; Norman, M. H.; Louis, J.-C.; Treanor, J. J. S. Identification and Biological Evaluation of AMG0347, ((E)-N-(7-Hydroxy-5,6,7,8- tetrahydronaphthalen-1-yl)-3-(2-(piperidin-1-yl)-6-(trifluoromethyl) pyridin-3-yl)acrylamide), a Potent Vanilloid Receptor 1 (TRPV1) Antagonist; Society for Neuroscience: Washington D.C., 2005; Abstract No. 292.16.
36. (a) Xi, N.; Bo, Y.; Doherty, E. M.; Fotsch, C.; Gavva, N.; Han, N.; Hungate, R. W.; Klionsky, L.; Liu, Q.; Tamir, R.; Xu, S.; Treanor, J. J. S.; Norman, M. H. Synthesis and Evaluation of Thiazole Carboxamides as Vanilloid Receptor 1 (TRPV1) Antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 5211-5217.
37. (b) Appendino, G.; Daddario, N.; Minassi, A.; Moriello, A. S.; Petrocellis, L. D.; Di Marzo, V. The Taming of Capsaicin. Reversal of the Vanilloid Activity of N-Acylvanillamines by Aromatic Iodination. J. Med. Chem. 2005, 48, 4663-4669.
38. (c) Suh, Y. G.; Oh, U. T.; Kim, H. D.; Lee, J. W.; Park, H. G.; Park, Y. H.; Yi, J. B. Novel Thiourea Compounds and the Pharmaceutical Compositions Containing the Same. WO 2002/16319 A1, 2002.
39. (d) Rami, H. K.; Thompson, M.; Macdonald, G. J. Westaway, S. M.; Mitchell, D. J. Vanilloid Receptor Modulators. WO 2003/068749 A1, 2003.
40. (e) Lee, C.-H.; Bayburt, E. K.; Didomenico, S., Jr.; Drizin, I.; Gomtsyan, A. R.; Koenig, J. R.; Perner, R, J.; Schmidt, R, G.; Turner, S. C.; White, T. K.; Zheng, G. Z. Fused Azabicyclic Compounds that Inhibit Vanilloid Receptor Subtype 1 (VR1) Receptor. WO 2003/070247 A1, 2003.
41. (f) Tajimi, M.; Kokubo, T.; Shiroo, M.; Tsukimi, Y.; Yara, T.; Urbahns, K.; Yamamoto, N.; Mogi, M.; Fujishima, H.; Masuda, T.; Yoshida, N.; Mori-Waki, T. Tetrahydro-Naphthalene Derivatives. WO 2004/ 052846 A1, 2004.
42. (g) Bakthavatchalam, R.; Blum, C. A.; Brielmann, H.; Darrow, J. W.; De Lombaert, S.; Yoon, T.; Zheng, Z. Substituted Biphenyl-4-carboxylic Acid Arylamide Analogues. WO 2005/056774 A2, 2005.
43. (h) Kuramochi, T.; Asai, N.; Ikegai, K.; Akamatsu, S.; Harada, H.; Ishikawa, N.; Shirakami, S.; Miyamoto, S.; Watanabe, T.; Kiso, T. Benzamide Derivative or Salt Thereof. WO 2004/110986 A1, 2004.
44. (i) Lee, J. W.; Kim, Y. H.; Kim, H.; Choi, H. K.; Ha, H. J. 4-(Methylsulfonylamino)phenyl Analogues as Vanilloid Antagonist Showing Excellent Analgesic Activity and the Pharmaceutical Compositions Comprising the Same. WO 2005/003084 A1, 2005.
45. (j) Kyle, D. J.; Sun, Q.; Tafesse L. Therapeutic Agents Useful for Treating Pain. WO 2005/004866 A1, 2005.
46. (k) Jamieson, C.; Miller, D. D.; Rami, H. K.; Tompson, M. Piperidine/Cyclohexane Carboxamide Derivatives for Use as Vanilloid Receptor Modulators. WO 2005/016915 A1, 2005.
47. (l) Kelly, M. G.; Janagani, S.; Wu, G.; Kincaid, J. Amide Compounds and Ion Channel Ligands and Uses Thereof. WO 2005/034870 A3, 2005.
48. (m) Bouchon, A.; Diedrichs, N.; Hermann, A.; Lustig, K.; Meier, H.; Pernerstorfer, J.; Reismuller, E.; Mogi, M.; Yura, T.; Fujishima, H.; Seki, M.; Koriyama, Y.; Yasoshima, K.; Misawa, K.; Tajimi, M.; Yamamoto, N.; Urbahns, K.; Hayashi, F.; Tsukimi, Y.; Gupta, J. Tetrahydro-naphthalene and Urea Derivatives. WO 2005/040100 A1, 2005.
49. (n) Bouchon, A.; Diedrichs, N.; Hermann, A.; Lustig, K.; Meier, H.; Pernerstorfer, J.; Reismuller, E.; De Vry, J.; Mogi, M.; Urbahns, K.; Yura, T.; Fujishima, H.; Tajimi, M.; Yamamoto, N.; Yuasa, H.; Gupta, J.; Tsukimi, Y.; Hayashi, F. Tetrahydro-naphthalene and Urea Derivatives. WO 2005/040119 A1, 2005.
50. (o) Lance, C.-H.; Koenig, J. R.; Brown, B. S. Amides that Inhibit Vanilloid Receptor Subtype 1 (VR1) Receptor. WO 2005/040121 A2, 2005.
51. (p) Mogi, M.; Fujishima, H.; Tajimi, M.; Yamamoto, N.; Urbahns, K.; Hayashi, F. Tsukimi, Y.; Gupta, J.; Yuasa, H.; Bicyclic Amide, Carbamate or Urea Derivatives as Vanilloid Receptor Modulators. WO 2005/0444786 A1, 2005.
52. (q) Hulme, C.; Ncube, M. V.; Norman, M. H.; Ognyanov, V. I.; Pettus, L. H.; Zhu, J. Bis Bicyclic Amides as Vanilloid Receptor Ligands and their Use in Treatment of Inflammatory and Neuropatic Pain. WO 2005/070885 A1, 2005.
53. (r) Norman, M. H.; Ognyanov, V.; Pettus, L. H. Vanilloid Receptor Ligands and Their Use in Treatments. WO 2005/072681 A2, 2005.
54. (s) Nagayama, S.; Shishido, Y.; Jinno, M.; Nakao, K. Substituted Benzamide Compounds as VR1 Receptor Antagonists. WO 2005/095329 A1, 2005.
55. (t) Yata, S.; Koga, Y.; Watanabe, T.; Matsuo, T.; Sakata, M.; Kondo, W. 3-Aminobenzamide Compound and Vanilloid Receptor 1 (VR1) Activity Inhibitor. WO 2006/006740 A2, 2006.
56. (a) Balan, C.; Bo, Y.; Dominguez, C.; Fotsch, C.; Gore, V. K.; Ma, V. V.; Norman, M. H.; Ognyanov, V. I.; Qian, Y.; Wang, X.; Xi, N.; Xu, S. Benzimidazole derivatives and their use as vanilloid receptor ligands. WO 2004/035549 A1, 2004.
57. (b) Sun, Q.; Tafesse, L.; Victory, S. Benzoazolylpiperazine derivatives having MGLUR1-and MGLUR5-antagonistic activity. WO 2004/058754 A1, 2004.
58. (c) Shao, B.; Huang, J.; Sun, Q.; Valenzano, K. J.; Schmid, L.; Nolan, S. 4-(2-PyridyI)piperazine-1-benzimidazoles as Potent TRPV1 Antagonists. Bioorg. Med. Chem. Lett. 2005, 15, 719-723.
59. (d) Ognyanov, V. I.; Balan, C.; Bannon, A.W.; Bo, Y.; Dominguez, C.; Fotsch, C.; Gore, V. K.; Klionsky, L.; Ma, V. M.; Qian, Y-X; Tamir, R. Wang, X.; Xi, N.; Xu, S.; Zhu, D.; Gavva, N. R.; Treanor, J. J. S.; Norman, M. H. Design of Potent, Orally Available Antagonists of Transient Receptor Potential Vanilloid 1. Structure-Activity Relationships of 2-(Piperazin-1-yl)-1H- benzimidazoles J. Med. Chem. 2006, 49 (12), 3719-3742.
60. (a) Bakthavatchalam, R. Capsaicin Receptor Ligands. WO 2002/ 08221 A1, 2002.
61. (b) Dax, S.; Dublin, A.; Jetter, M.; Nasser, N.; Shah, C.; Swanson, D.; Carruthers, N. I. Vanilloid Receptor Antagonists Structure-Activity Relationships via Parallel and Targeted Synthesis, Drugs Future 2002, 27 (Suppl. A), 93.
62. (c) Yura, T.; Mogi, M.; Ikegami, Y.; Masuda, T.; Kokubo, T.; Urbahns, K.; Yoshida, N.; Marumo, M.; Shiroo, M.; Tajimi, M.; Takeshita, K.; Moriwaki, T.; Tsukumi, Y. Piperazinecarboxamide Derivative. JP 2003/192673 A2, 2003.
63. (d) Tafesse, L.; Sun, Q.; Schmid, L.; Valenzano, K. J.; Rotshteyn, Y.; Su, Xi, Su.; Kyle, D. Synthesis and Evaluation of Pyridazinylpiperazines as Vanilloid Receptor 1 Antagonists. Bioorg. Med. Chem. Lett. 2004, 14, 5513-5519.
64. Gavva, N. R.; Tamir, R.; Qu, Y.; Klionsky, L.; Zhang, T. J.; Immke, D.; Wang, J.; Zhu, D.; Vanderah, T. W.; Porreca, F.; Doherty, E. M.; Norman, M. H.; Wild, K. D.; Bannon, A. W.; Louis, J.-C.; Treanor, J. J. S. AMG 9810 [(E)-3-(4-t-Butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a Novel Vanilloid Receptor 1 (TRPV1) Antagonist with Antihyperalgesic Properties. J. Pharmacol. Exp. Ther. 2005, 313, 474-484.
65. 23e
66. Zhu, J.; Viswanadhan, V.; Ognyanov, V.; Bo, Y.; Chen, N.; Chakrabarti, P.; Doherty, E.; Fotsch, C.; Gavva, N.; Han, N.; Klionski, L.; Liu, Q.; Tamir, R.; Wang, X.; Sun, Y.; Treanor, J. J. S.; Norman, M. H. Conformational Analyses of N-Aryl Cinnamides as TRPV1 Antagonists. American Chemical Society Division of Medicinal Chemistry, Abstracts, 229th National Meeting of the American Chemical Society, San Diego, CA, March 13-17, 2005; American Chemical Society: Washington, DC, 2005.
67. Boyd, D. B. In Reviews in Computational Chemistry; Lipkowitz, K. B., Boyd, D. B., Eds., VCH Publishers: New York, 1990; Vol. 1, pp 321-354.
68. Similar isosteric replacements of trans-cinnamides have also been reported by Wang, G. T.; Wang, S.; Gentles, R.; Sowin, T.; Leitza, S.; Reilly, E. B.; von Geldern, T. W. Amino-Substituted Heterocycles as Isosteres of trans-Cinnamides: Design and Synthesis of Heterocyclic Biaryl Sulfides as Potent Antagonists of LFA-1/CAM-1 Binding. Bioorg. Med. Chem. Lett. 2005, 15, 195-201.
69. (a) Doherty, E. M.; Zhu, J.; Stec, M.; Norman, M. H.; Kelly, M. G.; Fotsch, C. H.; Chen, N.; Chakrabarti, P. P.; Hungate, R. W. Amino-pyridine, -pyrimidine, and -pyridazine Derivatives for Use as Vanilloid Receptor Ligands for the Treatment of Pain. WO 2003/ 03099284 A1, 2003.
70. (b) Chakrabarti, P. P.; Chen, N.; Doherty, E. M.; Dominguez, C.; Falsey, J. R.; Fotsch, C. H.; Hulme, C.; Katon, J.; Nixey, T.; Norman, M. H.; Ognyanov, V. I.; Pettus, L. H.; Rzasa, R. M.; Stec, M.; Wang, H.; Zhu, J. Preparation of (Aryloxy)-pyrimidine and (Aryloxy)pyridazine as Vanilloid Receptor Ligands. WO 2004/014871 A1, 2004.
71. Klapars, A.; Huang, X.; Buchwald, S. L. A General and Efficient Copper Catalyst for the Amidation of Aryl Halides. J. Am. Chem. Soc. 2002, 124, 1144-1157.
72. 2 group on the lactam ring (as indicated below).
73. Almena, I.; Diaz-Ortiz, A.; Diez-Baria, E.; dl la Hoz, A.; Loupy, A. Solvent-Free Benzylations of 2-Pyridone. Regiospecific N- or C-Alkyation. Chem. Lett. 1995, 333-334.
74. Li, S. C.; Dixon, D. D. An Efficient Copper-Catalyzed Coupling Reaction of Pyridin-2-ones with Aryl and Heterocyclic Halides Based on Buchwald's Protocol. Tetrahedron Lett. 2004, 45, 4257-4260.
75. Miyaura, N.; Yanagi, T.; Suzuki, A. Palladium-Catalyzed Cross Coupling Reactions of Organoboron Compounds. Chem. Rev. 1995, 95, 2457-2483.
76. Wolfe, J. P.; Buchwald, S. L. Scope and Limitations of the Pd/BINAP-Catalyzed Animation of Aryl Bromides. J. Org. Chem. 2000, 65, 1144-1157.
77. Bryant, R. D.; Kung, F.-A.; South, M. S. J. Heterocycl. Chem. 1995, 32, 1473.
78. Coperet, C.; Adolfsson, H.; Khuong, T.-A. V.; Yudin, A. K.; Sharpless, K. B. A Simple and Efficient Method for the Preparation of Pyridine N-Oxides. J. Org. Chem. 1998, 63, 1740-1741.
79. Dean, W. D.; Blum, D. M. Condensation of Arylacetonitriles with Glyoxylic Acid. Facile Synthesis of Arylmaleic Acid Derivatives. J. Org. Chem. 1993, 58, 7916-7917.
80. Chapleo, C. B.; Doxey, J. C.; Myers, P. L.; Myers, M.; Smith, C. F. C.; Stillings, M. R. Effect of 1,4-Dioxanyl Substitution on the Adrenergic Activity of some Standard α-Adrenoreceptor Agents. Eur. J. Med. Chem. 1989, 24 (6), 619-622.
81. Miyashita, A.; Matsuda, H.; Matsuoka, Y.; Iwamoto, K.; Higashino, T. An Approach to the Synthesis of a Papaverin Analogue Containing a Quinazoline Ring System. Heterocycles 1995, 40 (2), 653-660.
82. Field, G.; Hammond, P. R. Method for Preparation of 7-Hydroxy-1,2,3,4- tetrahydroquinoline from 1,2,3,4-Tetrahydroquinoline. U.S. Patent 5,283,336, Feb 1, 1994.
83. The bisarylated compound (80; shown below) was obtained as the major product when 7-aminoquinoline (77) and 4-chloro-6-(4- (trifluoromethyl)phenyl)pyrimidine (72) were coupled under Buchwald conditions. Formation of this byproduct could be avoided by heating the two reagents (77 and 72) neat in a microwave, thereby resulting in increased yields of the desired mono-addition product (79).
84. Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. MacroModel - An Integrated Software System for Modeling Organic and Bioorganic Molecules using Molecular Mechanics. J. Comput. Chem. 1990, 11, 440-467.
85. Frisch, M. J.; et al. Gaussian 98, revision A.11.3; Gaussian, Inc.: Pittsburgh, PA, 2002.
86. (a) Halgren, T. A.; Nachbar, R. B. Merck Molecular Force Field. IV. Conformational Energies and Geometries for MMFF94. J. Comput. Chem. 1996, 17, 587-615.
87. (b) Halgren, T. A. MMFF VI. MMFF94s Option for Energy Minimization Studies. J. Comput. Chem. 1999, 20, 720-729.
88. Still, W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. Semianalytical Treatment of Solvation for Molecular Mechanics and Dynamics. J. Am. Chem. Soc. 1990, 112, 6127-6129.